Drug Database
LE

levodopa + benserazide (Madopar HBS / Levopar Plus / Prolopa)

✓ Approved

Roche · DDC · 小分子

什么是 levodopa + benserazide?

levodopa + benserazide 是一种小分子,由Roche研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Madopar HBS, Levopar Plus, Prolopa
公司Roche
药物类别小分子
分子靶点DDC
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

levodopa + benserazide 作用于 1 个分子靶点:

DDCdopa decarboxylase (AADC)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

levodopa + benserazide 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Nervous system disordersParkinson's disease✓ Approved

相关研究文献

PubMedNPJ biofilms and microbiomes2026-11-19

Modulation of gut microbiota by nardosinone augments the efficacy of levodopa in rotenone-induced Parkinson's disease rats.

Liu Mengmeng M, Xue Jingwen J, Cao Yuxin Y, Hao Zhuangzhuang Z et al.

Levodopa (L-DOPA) is the mainstay treatment for Parkinson's disease (PD), but its long-term use can cause adverse effects. Nardosinone enhances L-DOPA efficacy, yet the underlying mechanism is unclear. This study investigated whether the gut microbiota is associated with this synergism in a rotenone-induced PD rat model. Coadministration of nardosinone and L-DOPA increased L-DOPA and dopamine levels in the feces, plasma, and striatum of normal rats but not in antibiotic-treated rats with perturbed gut microbiota, suggesting a microbiota-correlated effect. Fecal microbiota transplantation from donors receiving the combination therapy alleviated motor deficits and dopaminergic neuron loss in recipient PD rats. This combination was associated with upregulated expression of tyrosine hydroxylase, DOPA decarboxylase, and their cofactors tetrahydrobiopterin and vitamin B6, as well as increased PINK1 and Parkin levels. It also reshaped the gut microbiota composition, enhanced intestinal and blood-brain barrier tight junction protein expression, and reduced c-Jun N-terminal kinase protein expression and neuroinflammation. In conclusion, these findings indicate that nardosinone coadministration is associated with alterations in the gut microbiota, improved barrier integrity markers, attenuated inflammation, and enhanced therapeutic effects of L-DOPA in this PD rat model. Definitive mechanistic pathways underlying the observed associations remain to be established.

PMID 43052303
阅读全文 →
PubMedFrontiers in neuroscience2026-11-18

De novo POLR2A p.(L1127F) variant presenting with neurodevelopmental regression and dystonia, with favorable response to low-dose dopamine therapy: a case report and literature review.

Cao Zhuci Z, Shen Qinru Q, Tangzhu Chenchen C, Guo Xiaohui X et al.

Neurodevelopmental disorder with hypotonia and variable intellectual and behavioral abnormalities (NEDHIB) is a rare autosomal-dominant condition caused by pathogenic POLR2A variants. It typically presents in infancy with hypotonia, developmental delay, and multisystem manifestations. Fewer than 40 patients have been reported worldwide, suggesting frequent misdiagnosis and underdiagnosis. To our knowledge, neurodevelopmental regression has not been documented in confirmed NEDHIB cases, and no standardized therapeutic regimens are established for clinical management. The patient presented with neonatal hypotonia and developmental delay. At 2 years and 4 months, she developed sleep-associated dystonia-like nodding and limb tremors that were initially suspected to represent epileptic seizures. By 3 years of age, she exhibited marked neurodevelopmental regression: loss of the ability to walk and sit independently, together with deterioration of language function. Electroencephalography (EEG) demonstrated background slowing accompanied by epileptiform discharges. Whole-exome sequencing identified a de novo heterozygous POLR2A variant c.3379C > T (p. L1127F), which confirmed the diagnosis of NEDHIB. Long-term rehabilitation training yielded only modest clinical benefits. After initiation of the dopamine agent levodopa-benserazide hydrochloride, marked improvements in motor and cognitive performance were observed, accompanied by the complete resolution of nodding episodes. With dose titration during follow-up, her clinical status remained stable without symptom relapse. This case expands the phenotypic spectrum associated with POLR2A-related NEDHIB and suggests that neurodevelopmental regression may occur within the phenotypic spectrum of this disorder. Our findings also highlight the potential benefit of low-dose dopamine therapy, offering novel insights into the clinical diagnosis, differential diagnosis, and therapeutic management of NEDHIB.

PMID 43047756
阅读全文 →
PubMedParkinsonism & related disorders2026-11-17

Efficacy, safety, and tolerability of inhaled levodopa (CVT-301) across age, timing of motor fluctuations, and treatment initiation in Parkinson's disease: Pooled analysis of three phase 3 trials.

Jimenez-Shahed Joohi J, Fernandez Hubert H HH, Lopez-Manzanares Lydia L, Pedrosa David D et al.

Most people with Parkinson's disease (PwP) eventually develop motor response fluctuations (OFF episodes) a few years after starting oral levodopa. CVT-301 is an inhaled levodopa formulation developed to alleviate OFF episodes. Assess the efficacy, safety, and tolerability of CVT-301 across subgroups by age and timing of treatment initiation using data from phase 3 clinical trials. This post hoc analysis pooled data from three phase 3 trials (CVT-301-004, CVT-301-005, and CVT-301-004E) involving PwP experiencing OFF episodes. Efficacy endpoints included the change in Unified Parkinson's Disease Rating Scale Part III (UPDRS-III) score from pre-dose to 30 min post-dose at week 12. Analyses were conducted across age subgroups (<55, 55-64, 65-74, ≥75 years at diagnosis and during study treatment) and timing of treatment initiation (early [<2 years] versus late [≥2 years]) in relation to the first OFF episode. Safety assessments focused on treatment-related cough and throat irritation. Data from 437 PwP were pooled. Mean (standard deviation [SD]) improvement in UPDRS-III score ranged from 5.7 (9.0) points in patients aged ≥75 years at diagnosis to 16.4 (13.8) points in those aged <55 years at study treatment initiation. Mean (SD) improvement in UPDRS-III score was 14.6 (12.0) and 14.7 (10.1) points in the early and late treatment initiation groups, respectively. Treatment-related cough (17.2%) and throat irritation (3.0%) were predominantly mild, transient, and rarely led to treatment modification. CVT-301 demonstrated consistent efficacy and favorable tolerability across the age and treatment-initiation subgroups evaluated in this analysis.

PMID 43044334
阅读全文 →
PubMedACS chemical biology2026-11-17

Inhibitors of Gut Bacterial l-Dopa Decarboxylation with Reduced Susceptibility to Host Metabolism.

Narayan Rohan R, Le Chi Chip CC, Khurana Jai K JK, Nieto Vincent V et al.

Microorganisms in the human gut influence the efficacy and metabolism of host-targeted small molecule therapeutics, including the frontline Parkinson's disease drug levodopa (l-dopa). Previous work has identified a mechanism-based inhibitor of gut bacterial decarboxylases that degrade l-dopa, α-fluoromethyltyrosine (AFMT). However, early experiments with AFMT in rodent models suggested undesirable in vivo metabolism by host tyrosine hydroxylase, producing α-fluoromethyldopa, a metabolite likely to worsen Parkinson's phenotypes and prevent application as an l-dopa cotreatment. Here, we demonstrate oxidation of AFMT to α-fluoromethyldopa in vitro by recombinant human tyrosine hydroxylase. We then develop AFMT analogues that retain activity against bacterial decarboxylases but have reduced susceptibility to host hydroxylation. Suitable arenes for inhibitor design were identified using assays with commercially available noncanonical amino acids, which revealed aryl difluorination as a promising modification. Difluoroaryl AFMT derivatives are less prone to degradation by tyrosine hydroxylase in vitro yet still inhibit l-dopa metabolism by bacterial decarboxylases. This work exemplifies how substrate reactivity can streamline design of mechanism-based enzyme inhibitors, as well as how constraints posed by the host can be incorporated during development of microbiome-targeted therapeutics. The compounds reported here are promising starting points for future studies in animal models and further exploration of gut bacterial effects on l-dopa treatment efficacy.

PMID 43044065
阅读全文 →
PubMedNPJ Parkinson's disease2026-11-16

Brain penetration of benserazide inversely associates with levodopa response in Parkinson's disease.

Lu Siqi S, Wu Lei L, Huang Qiaoying Q, Chen Ling L et al.

Levodopa combined with a peripheral DOPA decarboxylase inhibitor (DDCI) is the first-line treatment for Parkinson's disease (PD), yet interindividual response variability remains poorly understood. Whether DDCIs penetrate the central nervous system (CNS) in the context of potential blood-brain barrier (BBB) dysfunction in PD and influence levodopa efficacy is unclear. We therefore assessed CNS exposure of benserazide (BZ) and its active metabolite 2,3,4-trihydroxybenzylhydrazine (THBH) and their association with levodopa response. Fifteen PD patients (Hoehn-Yahr 2-3) underwent a standardized levodopa challenge test and were classified as good (≥50% improvement) or poor responders. Paired blood and cerebrospinal fluid (CSF) samples were collected after a single oral dose of levodopa/BZ (200/50 mg), and analyte concentrations were quantified using ultra-high-performance liquid chromatography with electrochemical detection (UPLC-ECD). Both BZ and THBH were detectable in CSF, indicating BBB penetration. CSF concentrations and CSF-to-plasma ratios of total BZ (BZ + THBH) were significantly higher in poor responders (p = 0.021 and 0.014, respectively) and negatively correlated with levodopa efficacy (p = 0.034 and 0.008, respectively). In contrast, levodopa concentrations and QAlb did not differ between groups. These findings demonstrate CNS exposure of BZ/THBH and suggest that increased central DDCI exposure may contribute to reduced levodopa responsiveness.

PMID 43035525
阅读全文 →
PubMedJournal of movement disorders2026-11-16

Levodopa-Induced Slow Dystonic Dyskinesia in a Patient With Progressive Supranuclear Palsy-Corticobasal Syndrome.

Dalal Deepika D, Ganguly Jacky J, Dutta Debayan D, Jha Shreyashi S et al.

PMID 43036069
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多levodopa + benserazide